Zhipu AI raises LLM prices by 30%+ amid strong demand. ChiNext AI ETF Huabao (159363) surges 2%+, with monthly AUM up 1.3B yuan. AI sector investment remains robust as market anticipates AGI advancement.
YouLianCloud leverages Qilin Financial LLM for GEOPlus solutions, restructuring content to EEAT standards. It helps financial institutions shift from voice competition to trust competition, becoming authoritative sources for AI models.
NewTimeSpace News: Nanjing Leads Biolabs Co., Ltd. (09887.HK) announced that the first patient dosing has been completed in the Phase Ib/II clinical trial of its core product Velixin™ (LBL-024) for the treatment of relapsed or metastatic triple-negative breast cancer, marking new progress in the development of this drug for breast cancer indications.
NewTimeSpace News, JIUYUAN GENE announced on February 9 that the Investigational New Drug (IND) application for JY54 Injection, a self-developed Class 1 chemical innovative drug, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. The drug is focused on weight management for obese or overweight populations and has demonstrated excellent preclinical data.
NewTimeSpace News: Peijia Medical Limited (09996.HK) announced on February 9, 2026 that the company has recently officially submitted the EU MDR CE mark registration application for its self-developed GeminiOne® Transcatheter Edge-to-Edge Repair System for the treatment of mitral regurgitation, marking progress in the product's global strategic layout. The registration application for the product in China has also been accepted, and it has obtained approval from the US FDA to initiate early clinical studies.
NewTimeSpace News, SKB BIO-B announced on February 6 that its core product TROP2 ADC sacituzumab govitecan (sac-TMT) has obtained approval from the National Medical Products Administration (NMPA) for the launch of its fourth indication, targeting the treatment of a specific type of HR+/HER2- breast cancer.
On February 4, 2026, affected by the sell-off in software stocks triggered by overseas AI automation tools, global e-commerce SaaS leader JST (06687.HK) recorded its largest single-day decline since listing. As of the close on February 5, the stock JST has cumulatively fallen 28.10% since its October 2025 IPO. The market is questioning whether AI will shrink pricing margins for software and destabilize the traditional subscription model, leaving the software industry facing a severe "replacement crisis."
NewTimeSpace News,HENLIUS announced in an announcement on February 5 that it has entered into a license agreement with Eisai, a listed Japanese pharmaceutical company, authorizing Eisai to develop, manufacture and commercialize Hansoh® (Serplulimab Injection) for the treatment of oncology indications in Japan.
Atomrobot filed for HKEX IPO with Huatai. Leading high-speed parallel robot maker, ranking first in China for five consecutive years per Frost & Sullivan.
InSilico Medicine has partnered with Qilu Pharmaceutical in a deal worth over HK$931 million to develop small molecule inhibitors for cardiovascular and metabolic diseases using its Pharma.AI platform, with milestone payments and single-digit sales royalties.
NewTimeSpace News: SSY Group Limited (02005.HK) released a voluntary announcement on the 26th stating that it has obtained the drug production registration approval from the National Medical Products Administration of China (NMPA) for the new 2ml specification of Potassium Dihydrogen Phosphate Complex Injection. Classified as a Class 3 chemical drug, the product is deemed to have passed the consistency evaluation.
NewTimeSpace News, HENGRUI PHARMA announced on January 26 that it has received the "Drug Clinical Trial Approval Notice" for SHR-1049 Injection issued by the National Medical Products Administration (NMPA), which grants approval for the drug to conduct a single-agent clinical trial for the treatment of advanced solid tumors.
IPLUSMOBOT Technology filed for HKEX IPO on Jan 23, 2026, ranking among the global top 5 industrial intelligent mobile robot players by order value. The company posted 2024 revenue of RMB 115 million (+53.2% YoY) and RMB 201 million for 9M 2025, with improving margins but ongoing losses. Backed by ByteDance and Lenovo, it targets R&D and global expansion with the proceeds.
ASIAINFO TECH disclosed in an announcement on January 26 that it has jointly established the "Embodied Intelligence Lab" with ABB Robotics, with technical support from Alibaba Cloud and NVIDIA. This marks the substantial implementation stage of the strategic cooperation between the two parties in the field of Physical AI (Physical Artificial Intelligence).
Guoyi Medical Technology has formally submitted an application for a Main Board listing on the Hong Kong Stock Exchange. As the leader of China's third-party SPD solution market, the company held a 29.2% market share in 2024. Financial data shows that its net profit surged 368% year-on-year to RMB 57.585 million in 2024. The company's business covers 116 hospitals across 13 provinces in China, with shareholders including iFlytek Venture Capital and Xinli Capital.
TIANGONG INT'L announced on January 16 that its subsidiary Tiangong Aihe has been approved to join the Fusion High-End Metal Materials R&D Joint Laboratory led by the Energy Research Institute of Hefei Comprehensive National Science Center, with a five-year validity period of the agreement. Tiangong Aihe will focus on two core R&D tasks, helping the Group explore downstream application areas of nuclear fusion and enrich its powder metallurgy business.
